About this episode
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Raising Health publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Raising Health
Moderna CEO Stéphane Bancel on the Next Era of mRNA
Raising Health
Clinical AI Comes of Age | Suchi Saria on the Future of Healthcare
Raising Health
AI, Healthcare, and 700 Million Patients | Nicolas Abad, Telepatía
Raising Health
Healthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
Raising Health